Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Iannone

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Blood|June 27, 2012
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Leukemia & Lymphoma|April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Blood|December 1, 2005
Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft directionKatharina Fleischhauer, Franco Locatelli, Marco Zecca, et al.
Blood Advances|June 6, 2024
More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS studyGualtiero Palareti, Sophie Testa, Cristina Legnani, et al.
Blood Advances|February 23, 2024
Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS studySophie Testa, Gualtiero Palareti, Cristina Legnani, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Blood|June 27, 2012
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Leukemia & Lymphoma|April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Blood|December 1, 2005
Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft directionKatharina Fleischhauer, Franco Locatelli, Marco Zecca, et al.
Blood Advances|June 6, 2024
More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS studyGualtiero Palareti, Sophie Testa, Cristina Legnani, et al.
Blood Advances|February 23, 2024
Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS studySophie Testa, Gualtiero Palareti, Cristina Legnani, et al.
Pageof 2